Revotar Biopharmaceuticals AG

September 21, 2011 04:24 ET

Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the European Respiratory Society Annual Congress 2011 in Amsterdam

BERLIN and HENNIGSDORF, GERMANY--(Marketwire - Sep 21, 2011) -

Revotar Biopharmaceuticals AG / Positive multi-center COPD trial with inhaled Bimosiamose to be presented at the European Respiratory Society Annual Congress 2011 in Amsterdam . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Revotar Biopharmaceuticals AG recently announced that it successfully completed a multi-center Phase II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Data have been accepted for the late breaking news session at the upcoming annual congress of the European Respiratory Society (ERS) in Amsterdam and will be presented by the research group of Prof. Helgo Magnussen in an oral presentation Tuesday, September 27th during Session 460 (14:45-16:45, Forum).

As previously released, inhalation of Bimosiamose for 28 days on top of standard bronchodilators was safe and well tolerated in 77 patients with moderate to severe COPD (GOLD II-III). It led to a broad and significant attenuation of airway inflammation and trend towards lung function improvements.

"Our data with Bimosiamose demonstrate a significant step forward in the anti- inflammatory treatment of COPD", said Prof. Wolfgang Meyer-Sabellek, CMO of Revotar. "We will discuss future clinical development of our first in class inhaled drug with international key opinion leaders in Amsterdam at one of the biggest and renowned respiratory conferences worldwide."

"We are encouraged that our data are appreciated by the scientific community as a major milestone on the way towards the establishment of pan- selectin antagonism as a novel therapeutic option in COPD", added Dr. Martin Pöhlchen, CEO of Revotar.

About COPD

Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting the lung. According to the WHO, estimated 64 million people have COPD worldwide in 2004. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that COPD will become the third leading cause of death worldwide by 2030. In 2010, the global COPD market recorded sales of approximately 11 billion US-$. There is a high unmet medical need in drugs modifying the underlying inflammation in COPD.


About Revotar Biopharmaceutical AG

Revotar develops innovative drugs for inflammatory indications such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in COPD, asthma, and psoriasis with a good safety and efficacy profile in over 300 patients and volunteers. Furthermore Revotar has two preclinical programs addressing respiratory and other inflammatory diseases.

Press Release (PDF): http://hugin.info/143207/R/1548488/475879.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE

[HUG#1548488]

Contact Information

  • Contact Address:
    Dr Martin Pohlchen
    CEO
    Revotar Biopharmaceuticals AG
    Neuendorfstr. 24a
    D-16761 Hennigsdorf / Germany
    Phone: 3302-2025010
    Fax: 3302-2025030
    Email: Email Contact
    www.revotar.com